A detailed history of Bank Of America Corp transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Bank Of America Corp holds 362,137 shares of BEAM stock, worth $9.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
362,137
Previous 321,052 12.8%
Holding current value
$9.8 Million
Previous $10.6 Million 20.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $871,823 - $1.34 Million
41,085 Added 12.8%
362,137 $8.48 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $2.97 Million - $5.71 Million
126,724 Added 65.21%
321,052 $10.6 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $283,782 - $493,451
16,042 Added 9.0%
194,328 $5.29 Million
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $5.84 Million - $7.17 Million
-199,334 Reduced 52.79%
178,286 $5.69 Million
Q1 2023

May 12, 2023

BUY
$30.15 - $48.79 $6.44 Million - $10.4 Million
213,502 Added 130.09%
377,620 $11.6 Million
Q4 2022

Feb 10, 2023

BUY
$36.73 - $51.6 $1.63 Million - $2.29 Million
44,343 Added 37.02%
164,118 $6.42 Million
Q3 2022

Nov 14, 2022

SELL
$39.79 - $70.31 $735,518 - $1.3 Million
-18,485 Reduced 13.37%
119,775 $5.71 Million
Q2 2022

Aug 12, 2022

BUY
$29.86 - $62.36 $16,333 - $34,110
547 Added 0.4%
138,260 $5.35 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $1.53 Million - $2.34 Million
28,450 Added 26.04%
137,713 $7.89 Million
Q4 2021

Feb 08, 2022

BUY
$68.02 - $99.06 $6.25 Million - $9.1 Million
91,841 Added 527.16%
109,263 $8.71 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $176,080 - $278,823
2,087 Added 13.61%
17,422 $1.52 Million
Q2 2021

Sep 13, 2021

BUY
$64.12 - $128.71 $983,280 - $1.97 Million
15,335 New
15,335 $1.97 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.9B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.